Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

Recruiting now

Conditions studied: Adjuvant Chemotherapy

In brief

This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.

Key facts

Study ID

NCT06389552

Run by

HK inno.N Corporation

People needed

36

Starts

2023-09-25

Expected to finish

2027-12-01

Last updated by the study team

2024-04-29

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age over 19 at the time of obtaining the informed consent form
• Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
• ECOG 0 or 1
• Scheduled to RO or R1 resection
• Organ function capable of chemotherapy

You may not qualify if…

• FOLFIRINOX contraindications among the drug approval requirements
• Palliative Therapy
• Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX

Where it is running

• Seoul ST. Mary's Hospital — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.